Treatment of infective endocarditis: a 10-year comparative analysis.

James V. Richardson, Robert B. Karp, John W. Kirklin, William E. Dismukes

Circulation · 1978 · 367 citations · 15 references

Concepts

TL;DR

Heart failure, annular and myocardial abscesses, heart block, and coronary embolism—most common in staphylococcal and fungal endocarditis—are the leading causes of death in native and prosthetic valve infective endocarditis. The study analyzed surgical versus non‑surgical treatment outcomes in 182 patients with active infective endocarditis over a 10‑year period. Surgery markedly improved survival in native valve endocarditis patients with moderate or severe heart failure and all staphylococcal cases, and in prosthetic valve endocarditis patients with moderate or severe heart failure and late PVE, prompting recommendations for early surgery and valve replacement in these groups.

Abstract

The results of surgical and non-surgical treatment of active infective endocarditis in 182 patients over a 10-year period were analyzed. Heart failure, annular and myocardial abscesses, heart block, and coronary embolism, seen most frequently with staphylococcal and fungal endocarditis, were the primary causes of death in both native valve endocarditis (NVE) and prosthetic valve endocarditis (PVE). In NVE, surgery significantly improved the survival in patients with moderate or severe heart failure (P less than 0.05) and in all patients with staphylococcal endocarditis (P less than 0.03). In PVE, surgery significantly influenced survival in patients with moderate or severe heart failure (P less than 0.05) and in the entire group with late PVE (P less than 0.01). Early surgery is recommended for patients with native valve endocarditis and moderate or severe heart failure; those patients with staphylococcal NVE, regardless of hemodynamic state, should undergo early valve replacement. Early surgery is recommended for PVE patients with moderate or severe heart failure. We also recommend early valve replacement for early and late staphylococcal PVE.

References

15